Patents by Inventor Michael C YI

Michael C YI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Knockdown or knockout of one or more of TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK to mitigate t cell recognition of allogeneic cell products
    Patent number: 12577283
    Abstract: Provided herein are engineered immune cells and populations thereof for administration to patients to treat cancer (e.g., solid tumors or liquid tumors) and other conditions. The cells are engineered to functionally express a reduced level of one or more of RFX5, NLRC5, TAP2, ?2m, TRAC, RFXAP, CIITA and RFXANK. The cells optionally are further engineered to express one or more than one additional protein such as an antigen binding protein (e.g., a chimeric antigen receptor (CAR) or T cell receptor) to target tumor cells or other damaged cells in the patient and/or to express other genes at a reduced level. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering the cells and the compositions.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: March 17, 2026
    Assignee: Allogene Therapeutics, Inc.
    Inventors: Michael Thomas Bethune, Eric Hans Gschweng, Thomas John Van Blarcom, Cesar Adolfo Sommer, Michael C Yi
  • KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
    Publication number: 20220251505
    Abstract: Provided herein are engineered immune cells and populations thereof for administration to patients to treat cancer (e.g., solid tumors or liquid tumors) and other conditions. The cells are engineered to functionally express a reduced level of one or more of RFX5, NLRC5, TAP2, ?2m, TRAC, RFXAP, CIITA and RFXANK. The cells optionally are further engineered to express one or more than one additional protein such as an antigen binding protein (e.g., a chimeric antigen receptor (CAR) or T cell receptor) to target tumor cells or other damaged cells in the patient and/or to express other genes at a reduced level. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering the cells and the compositions.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 11, 2022
    Inventors: Michael Thomas BETHUNE, Eric Hans GSCHWENG, Thomas John VAN BLARCOM, Cesar Adolfo SOMMER, Michael C YI